☆ 4.6 Article

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Hematology

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population

Camille C. B. Kockerols et al.

HAEMATOLOGICA (2023)

添加到收藏夹

Review Hematology

Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia- What to look for when treatment-free remission is not an option

Jeffrey H. Lipton et al.

Summary: The development of BCR::ABL1-targeting tyrosine kinase inhibitors has improved the prognosis of patients with chronic myeloid leukemia. Differences in safety profiles between TKIs allow for personalized treatment plans based on various factors. This review summarizes the safety profiles of currently approved TKIs and their impact on treatment selection, as well as strategies to manage adverse events and comorbidities.

BLOOD REVIEWS (2022)

添加到收藏夹

Review Oncology

Development of asciminib, a novel allosteric inhibitor of BCR-ABL1

Delphine Rea et al.

Summary: This article discusses the mechanism and clinical challenges of chronic myeloid leukemia, as well as the development and potential application of a new drug called Asciminib.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors

Valentin Garcia-Gutierrez et al.

Summary: This review discusses the potential of a new BCR::ABL1 inhibitor, asciminib, in the treatment of chronic myeloid leukemia (CML) patients. The drug has the ability to overcome resistance/intolerance and has shown promising efficacy in CML patients who have failed at least two TKIs.

EXPERT REVIEW OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

Elias Jabbour et al.

Summary: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by a genetic translocation and fusion gene. Tyrosine kinase inhibitors (TKIs) are the frontline therapy, but second-line options are available for patients who develop resistance. Stem cell transplantation and non-TKI agents are recommended for advanced disease and relapse patients.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Education, Scientific Disciplines

Management of TKI-resistant chronic phase CML

Timothy P. Hughes et al.

Summary: For chronic phase CML patients who are resistant to multiple TKIs, both dose-modified ponatinib and asciminib are excellent treatment options. Lower doses of ponatinib can reduce the risk of serious vascular occlusive events, while higher doses of both ponatinib and asciminib are critical for patients with the T315I mutation. The choice of the best drug and dose can be challenging in different clinical situations and requires evaluation based on the latest trial evidence.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

添加到收藏夹

Review Oncology

A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase

Valentin Garcia-Gutierrez et al.

Summary: This article discusses the treatment strategies and challenges of using tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia (CML). It covers treatment choices at initial diagnosis, options after treatment failure, and the importance of treatment-free remission. Additionally, considering the timing of writing during the COVID-19 pandemic, the article addresses global challenges and the advent of newer therapies.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

A. Luna et al.

Summary: Asciminib has shown good efficacy and safety in patients with chronic myeloid leukemia, including those previously treated with ponatinib. However, resistance to asciminib remains a challenge, particularly in patients previously treated with ponatinib.

ANNALS OF HEMATOLOGY (2022)

添加到收藏夹

Letter Oncology

Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Valentin Garcia-Gutierrez et al.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Review Oncology

Future Directions in Chronic Phase CML Treatment

Nathalie Javidi-Sharifi et al.

Summary: This review focuses on recent and emerging treatment paradigms in chronic phase CML, covering new frontline approaches, second treatment-free remission studies, and refractory disease treatment. Specific treatment methods include immunomodulatory approaches, targeting leukemia stem cells, and BCR-ABL1-intrinsic combination therapy. The challenges remain with regard to deepening initial responses, prolonging treatment-free remission, and providing efficacious and tolerable options for patients with refractory disease and resistance mutations.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)

添加到收藏夹

Article Hematology

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Rea et al.

Summary: Asciminib demonstrated superior efficacy compared to bosutinib in treating patients with CML-CP who are resistant or intolerant to >= 2 prior TKIs, with a favorable safety profile.

BLOOD (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Asciminib: an investigational agent for the treatment of chronic myeloid leukemia

Massimo Breccia et al.

Summary: Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for CML patients, but resistance and intolerance can still be issues. Asciminib, an allosteric inhibitor, shows promise as a third-line treatment option, particularly for patients with the T315I mutation.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Review Oncology

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

A. Hochhaus et al.

LEUKEMIA (2020)

添加到收藏夹

Review Oncology

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

Paul W. Manley et al.

LEUKEMIA RESEARCH (2020)

添加到收藏夹

Review Oncology

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

Valentin Garcia-Gutierrez et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants

Christopher A. Eide et al.

CANCER CELL (2019)

添加到收藏夹

Review Oncology

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

Federica Loscocco et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

T. P. Hughes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Hematology

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial

Jorge E. Cortes et al.

BLOOD (2018)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial

Jorge E. Cortes et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

A. Hochhaus et al.

LEUKEMIA (2016)

添加到收藏夹

Review Oncology

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

J. L. Steegmann et al.

LEUKEMIA (2016)

添加到收藏夹

Article Medicine, General & Internal

Chronic myeloid leukaemia

Jane F. Apperley

LANCET (2015)

添加到收藏夹

Article Hematology

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

Tim H. Bruemmendorf et al.

BRITISH JOURNAL OF HAEMATOLOGY (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Drug discovery and the human kinome: Recent trends

Richard Eglen et al.

PHARMACOLOGY & THERAPEUTICS (2011)

添加到收藏夹

Review Medical Laboratory Technology

Tyrosine kinase inhibitors in cancer therapy

S Madhusudan et al.

CLINICAL BIOCHEMISTRY (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.